Ambery P - Search Results

1

Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.

Heerspink HJL, Greasley PJ, Ahlström C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnåker M, Turton M, Wheeler DC, Ambery P. Heerspink HJL, et al. Among authors: ambery p. Nephrol Dial Transplant. 2024 Feb 28;39(3):414-425. doi: 10.1093/ndt/gfad183. Nephrol Dial Transplant. 2024. PMID: 37632201 Free PMC article. Clinical Trial.

2

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.

Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P. Heerspink HJL, et al. Among authors: ambery p. Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931629 Clinical Trial.

3

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study.

Lee NHC, Kiddle SJ, Chandankhede S, Agrawal S, Bean DM, Hunt PR, Parker VER, Greasley PJ, Ambery P. Lee NHC, et al. Among authors: ambery p. BMJ Open Gastroenterol. 2023 Nov 29;10(1):e001234. doi: 10.1136/bmjgast-2023-001234. BMJ Open Gastroenterol. 2023. PMID: 38030407 Free PMC article.

4

A comprehensive analysis of liver safety across zibotentan oncology trials: knowledge of the past offers new perspectives on the present.

Fettiplace A, Matis-Mitchell S, Molodetskyi O, Söderbergh M, Oscarsson J, Lin M, Ravikiran S, Billger M, Ambery P. Fettiplace A, et al. Among authors: ambery p. Expert Opin Drug Saf. 2024 Apr;23(4):477-486. doi: 10.1080/14740338.2024.2328816. Epub 2024 Mar 24. Expert Opin Drug Saf. 2024. PMID: 38469902

5

Co-localization of the sodium-glucose co-transporter-2 channel (SGLT-2) with endothelin ETA and ETB receptors in human cardiorenal tissue.

Williams TL, Kuc RE, Paterson AL, Abraham GR, Pullinger AL, Maguire JJ, Sinha S, Greasley PJ, Ambery P, Davenport AP. Williams TL, et al. Among authors: ambery p. Biosci Rep. 2024 Jun 26;44(6):BSR20240604. doi: 10.1042/BSR20240604. Biosci Rep. 2024. PMID: 38747277 Free article.

6

Perspectives in weight control in diabetes - SGLT2 inhibitors and GLP-1-glucagon dual agonism.

Iqbal N, Ambery P, Logue J, Mallappa A, Sjöström CD. Iqbal N, et al. Among authors: ambery p. Diabetes Res Clin Pract. 2023 May;199:110669. doi: 10.1016/j.diabres.2023.110669. Epub 2023 Apr 17. Diabetes Res Clin Pract. 2023. PMID: 37075928 Free article.

7

Metabolic adverse events associated with systemic corticosteroid therapy-a systematic review and meta-analysis.

Kulkarni S, Durham H, Glover L, Ather O, Phillips V, Nemes S, Cousens L, Blomgran P, Ambery P. Kulkarni S, et al. Among authors: ambery p. BMJ Open. 2022 Dec 22;12(12):e061476. doi: 10.1136/bmjopen-2022-061476. BMJ Open. 2022. PMID: 36549729 Free PMC article.

8

Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table.

Cosentino F, Verma S, Ambery P, Treppendahl MB, van Eickels M, Anker SD, Cecchini M, Fioretto P, Groop PH, Hess D, Khunti K, Lam CSP, Richard-Lordereau I, Lund LH, McGreavy P, Newsome PN, Sattar N, Solomon S, Weidinger F, Zannad F, Zeiher A. Cosentino F, et al. Among authors: ambery p. Eur Heart J. 2023 Oct 14;44(39):4141-4156. doi: 10.1093/eurheartj/ehad445. Eur Heart J. 2023. PMID: 37448181

9

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver.

Newsome PN, Ambery P. Newsome PN, et al. Among authors: ambery p. J Hepatol. 2023 Dec;79(6):1557-1565. doi: 10.1016/j.jhep.2023.07.033. Epub 2023 Aug 9. J Hepatol. 2023. PMID: 37562748 Free article. Review.

10

Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.

Lindsay RT, Ambery P, Jermutus L, Murray AJ. Lindsay RT, et al. Among authors: ambery p. Physiol Rep. 2023 Mar;11(6):e15597. doi: 10.14814/phy2.15597. Physiol Rep. 2023. PMID: 36946315 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

54 results

Search Page